# Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

> **NCT05321212** · — · COMPLETED · sponsor: **University Hospital, Brest** · enrollment: 108 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Immunotherapy

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05321212
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-02
- **Primary completion:** 2019-01-02
- **Final completion:** 2019-03-02
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321212, "Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)". Retrieved via AI Analytics 2026-09-27 from https://api.ai-analytics.org/clinical/NCT05321212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*